Strong Earnings Growth At Yamanouchi

29 May 1997

The Japanese pharmaceutical company Yamanouchi has reported stronggrowth for the year to March 31. On a consolidated basis, net sales advanced 9.8% to 454.7 billion yen ($3.9 billion), net profits rose 3.3% to 41.9 billion yen, and operating income was 92.5 billion yen, an increase of 12.9%. Ordinary (or recurring) income grew 13.3% to 92.9 million yen.

The firm's pharmaceutical division achieved turnover of 359.6 billion yen, up 6.9% on the previous fiscal year. Pharmaceutical operating income grew 11.1% to just under 83 billion yen. Its nutritional products achieved revenues of 54.5 billion yen, up 18.5%, and operating income was 4.1 billion yen, slipping 1.3%. The firm's third business division, food and roses, made turnover during the year of 35.8 billion yen, up 27.9%. Its operating income was 2.9 billion yen, an increase of 214%. Other businesses achieved revenues of 4.8 billion yen, up 28.1%, and operating income of 1.9 billion yen, a rise of 24.2%.

Geographically, Yamanouchi achieved domestic turnover of 324.4 billion yen, up 4.9%. Operating profits were ahead 10% to 69.9 billion yen. International sales grew 24.1% to 130.3 billion yen, with foreign operating income of 23.5 billion yen, up 27.3%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight